fda safety communication semaglutide naion 2025 drug The FDA just closed a 2-year investigation into Ozempic NAION Lawsuit - LitigationConnect

Effects of bariatric surgery on mortality in Swedish Obese Subjects

Some patients sought medical attention or required hospitalization

Allow it to air dry

Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability

Irfan Khan, MD , provides guidance to help you choose the most effective treatment for your needs

The same drugs, made in the same factories, at the same dosages, are costing Americans up to 1,000% more than in any other country